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Deciphering immune events during early stages of human immunodeficiency virus type 1 (HIV-1) infection
is critical for understanding the course of disease. We characterized the hierarchy of HIV-1-specific T-cell
gamma interferon (IFN-) enzyme-linked immunospot (ELISPOT) assay responses during acute subtype C
infection in 53 individuals and associated temporal patterns of responses with disease progression in the first
12 months. There was a diverse pattern of T-cell recognition across the proteome, with the recognition of Nef
being immunodominant as early as 3 weeks postinfection. Over the first 6 months, we found that there was a
23% chance of an increased response to Nef for every week postinfection (P  0.0024), followed by a
nonsignificant increase to Pol (4.6%) and Gag (3.2%). Responses to Env and regulatory proteins appeared to
remain stable. Three temporal patterns of HIV-specific T-cell responses could be distinguished: persistent, lost,
or new. The proportion of persistent T-cell responses was significantly lower (P  0.0037) in individuals
defined as rapid progressors than in those progressing slowly and who controlled viremia. Almost 90% of lost
T-cell responses were coincidental with autologous viral epitope escape. Regression analysis between the time
to fixed viral escape and lost T-cell responses (r  0.61; P  0.019) showed a mean delay of 14 weeks after viral
escape. Collectively, T-cell epitope recognition is not a static event, and temporal patterns of IFN--based
responses exist. This is due partly to viral sequence variation but also to the recognition of invariant viral
epitopes that leads to waves of persistent T-cell immunity, which appears to associate with slower disease
progression in the first year of infection.
For more than a decade, there has been a wealth of evidence
to show that human immunodeficiency virus (HIV)-specific
cytotoxic T-cell (CTL) responses play a role in the control of
HIV-1 and simian immunodeficiency virus (SIV) infection. In
humans, the first appearance of CTL in primary HIV-1 infec-
tion coincides with the decline of peak viremia (7, 27), while
depletion of CD8 T cells in SIV infection resulted in elevated
viremia (45). Additionally, polymorphisms in HLA class I-re-
stricted CTL responses are associated with differential HIV-1
disease outcomes (25), and the emergence of viral escape
within CTL epitopes during acute and chronic SIV or HIV-1
infection demonstrates the effectiveness of CD8 T cells to
exert viral selection pressure (21). Dissecting the specificity of
HIV-1-specific CD8 T-cell responses that associate with
the control of viral replication during acute/early infection is
thought to be critical for the design of vaccines and potential
immunotherapeutic strategies aimed at stimulating these re-
sponses.
Preferential targeting of class I-restricted CTL epitopes in
Gag during early and chronic HIV-1 infection has been asso-
ciated with lower viral loads (15, 25, 34, 48, 55), whereas Env-
and Nef-specific CD8 T-cell responses have been associated
with higher viremia (15, 34, 55). Increasing evidence suggests
that patterns of immunodominant HIV-specific CD8 T-cell
responses restricted by specific HLA alleles are major deter-
minants of the viral set point (47). In addition, Goonetilleke et
al. (17) have provided insight into the rapidity of early escape
and the contribution of the first HIV-specific CD8 T-cell
responses to the transmitted/founder virus in control of acute
viremia. The restriction of CTL epitopes by HLA-B*5801, for
example, has also been associated with better viral control
(16, 24). However, the temporal nature of epitope-specific
responses that associate with viral control has not been ex-
plored. Recently, we found no association between the mag-
nitude and breadth of gamma interferon (IFN-) enzyme-
linked immunospot (ELISPOT) assay responses at a static
3-month time point with the viral set point at 12 months (22).
The unpredictability of early T-cell responses with later viral
control could be a result of HIV variability resulting in epitope
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escape from humoral and T-cell pressure (1, 8). For example,
the impact of CTL pressure on shaping viral diversity at a
human population level has been observed through HLA im-
printing (6, 9, 44), and several studies have shown that certain
selected escape mutations can compromise viral fitness (10, 29,
33, 39). Other studies have also demonstrated that the selec-
tion of escape variants in chronic HIV-1 and SIV infection can
result in the loss of immune control and disease progression (3,
20). Assessing the nature of T-cell responses longitudinally and
relating the patterns of contemporaneous viral recognition
with viral diversity may represent alternative insights into fac-
tors associated with set point and disease progression.
As the global AIDS epidemic continues to expand in sub-
Saharan Africa, and South Africa in particular, the need to
implement a preventive vaccine through the public health sec-
tor remains paramount. To date, several prototype antibody
and T-cell-based candidate vaccine trials have been completed
worldwide (37), and the recent failure of a phase IIb Ad5-Gag-
Pol-Nef HIV-1 vaccine trial has emphasized the challenge of
producing an effective T-cell-based vaccine against HIV. Data
from the recent ALVAC and AIDSVAX (RV144) trials in
Thailand have provided modest efficacy of a vaccine regimen in
reducing HIV infection (42), and while the immune mecha-
nisms for this are as yet unclear, these findings have created a
platform for identifying immune responses that correlate with
protection.
The identification of the earliest targets of T cells during
acute HIV-1 infection would be helpful in understanding the
evolution of immunity when a host first encounters the virus
and also would provide insight into the host-pathogen interplay
when there is a rapidly changing target. We describe some of
the earliest T-cell responses that occur during acute subtype C
HIV-1 infection, how these change over time and associate
with early disease progression, as well as the kinetics of these
changes in relation to autologous viral escape.
MATERIALS AND METHODS
Study subjects. The cohort consisted of 53 HIV-1 clade C-infected subjects
enrolled as part of the Centre for AIDS Programme Research in South Africa
(CAPRISA) 002 acute infection study in Durban, South Africa, as previously
reported (52). The date of HIV infection was either estimated by a prospective
RNA-positive/antibody-negative measurement or set as the midpoint between
the last antibody-negative and first antibody-positive enzyme-linked immunosor-
bent assay (ELISA) test. Herein, we report on the data from events within the
first 12 months of infection. Viral load was measured with the COBAS Amplicor
HIV-1 monitor test, version 1.5 (Roche Diagnostics, Branchburg, NJ), and the
CD4 count was measured by flow cytometry. The studied subjects were esti-
mated to have been infected for a median duration of 6 weeks, ranging from 2 to
15 weeks postinfection at enrollment (22). The median plasma viral load at
enrollment was 75,600 HIV RNA copies/ml (range, 547 to 5,510,000), and the
median CD4 count was 494 cells/mm3 (range, 197 to 989). The University of
KwaZulu-Natal, University of Witwatersrand, and University of Cape Town
institutional review boards approved this study, and all the subjects provided
written informed consent for participation in this study.
HLA typing. High-resolution HLA class I genotyping was performed by se-
quencing of exons 2, 3, and 4 using Atria Allele SEQR kits (Abbott Diagnostics)
and Assign SBT 3.5 software (Conexio Genomics) as described previously (10).
Synthetic subtype C HIV-1 peptides. Peptide sets spanning the entire HIV-1
clade C proteome corresponding to gene products from the HIV-1 consensus C
(Gag, Vif, Vpr, and Vpu), isolate Du151 (Pol, Nef, Tat, and Rev), and isolate
Du179 (gp160 Env) were synthesized and dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 10 mg/ml as previously described (34). The
peptide sets based on Du151 were sequences matching clade C vaccine candi-
dates in clinical trials (54).
Cell preparations. Peripheral blood mononuclear cells (PBMC) were isolated
by standard Ficoll-Hypaque density gradient centrifugation (Amersham Phar-
macia, Uppsala, Sweden) and used immediately in an ELISPOT assay, and the
rest were cryopreserved in 90% heat-inactivated fetal bovine serum (FBS; In-
vitrogen, Paisley, United Kingdom) plus 10% DMSO and stored in liquid nitro-
gen until needed for further analysis.
ELISPOT assay. HIV-1-specific T-cell responses were quantified by IFN-
ELISPOT assay using a set of 432 overlapping peptides spanning the entire
HIV-1 C proteome arranged in a pool matrix format as previously described (22,
34). Briefly, freshly isolated PBMC were stimulated with HIV-1 peptide pools (2
g/ml), cytomegalovirus, Epstein-Barr virus, and influenza virus (CEF) pools (1
g/ml), and phytohemagglutinin (4 g/ml), incubated overnight at 37°C with 5%
CO2, and developed as previously described. Confirmation of positive responses
at the single-peptide level within peptide pools was undertaken in a second
ELISPOT assay and monitored longitudinally for selected participants. The CTL
epitopes within peptides showing responses were predicted from the published
epitopes on the HIV immunology database based on the matched HLA from the
participants.
Sequencing of autologous virus. Viral sequencing was carried out as previously
described (10). RNA isolated from plasma samples using the MagNA Pure
compact nucleic extractor (Roche) was reverse transcribed using the Invitrogen
ThermoScript reverse transcription kit (Invitrogen) and the primers Gag D
reverse (5-AAT TCC TCC TAT CAT TTT TGG-3; HXB position 2382 to
2402) and Nef O reverse (5-AGG CAA GCT TTA TTG AGG-3; HXB position
9608 to 9625) for nef. Limiting-dilution nested PCR was carried out by serial
endpoint dilution of the cDNA (43). The first-round PCR primers were Gag D
forward (5-TCT CTA GCA GTG GCG CCC G-3; HXB position 626 to 644)
and Gag D reverse (5-AAT TCC TCC TAT CAT TTT TGG-3; HXB position
2382 to 2402). The second-round PCR primers were Gag A forward (5-CTC
TCG ACG CAG GAC TCG GCT T-3; HXB position 683 to 704) and Gag C
reverse (5-TCT TCT AAT ACT GTA TCA TCT GC-3; HXB position 2334 to
2356). For nef, the first-round PCR primers were SQ15FC (5-GAG AGC GGT
GGA ACT TCT-3; HXB position 8561 to 8578) and Nef O reverse. The
second-round PCR primers were Nef forward (5-CCT AGA AGA ATA AGA
CAG GGC TT-3; HXB position 8754 to 8776) and Nef reverse (5-CCT GGA
ACG CCC CAG TGG-3; HXB position 9443 to 9461). PCR products were
either directly sequenced or cloned using the pGEM-T Easy vector system
(Promega). Sequencing was carried out using an ABI Prism dye terminator cycle
sequencing kit (Applied Biosysytems) and the primers Gag A forward, Gag A
reverse (5-ACA TGG GTA TCA CTT CTG GGC T-3; HXB position 1282 to
1303), Gag B forward (5-CCA TAT CAC CTA GAA CTT TGA AT-3; HXB
position 1226 to 1246), Gag B reverse (5-CTC CCT GAC ATG CTG TCA TCA
T-3; HXB position 1825 to 1846), Gag C forward (5-CCT TGT TGG TCC
AAA ATG CGA-3; HXB position 1748 to 1768), and Gag C reverse for direct
sequencing. Sequences were assembled using ChromasPro and aligned using
ClustalW (with default settings) (49).
Statistical analysis. Statistical analysis and graphical presentation were per-
formed using InStat, GraphPad Prism version 3.0 software, and SAS version 9.1.3
(SAS Institute, Inc., Cary, NC). Data are expressed as medians  ranges and
analyzed by the use of nonparametric statistics. Statistical analysis of significance
was based on two-tailed t tests using either Mann-Whitney or Kruskal-Wallis
analysis of variance (Dunn’s test) for multiple comparisons. The frequency of
recognition was modeled using generalized estimating equations (GEE), using a
binomial distribution and a logit link, effectively modeling a logistic regression
model and adjusting for repeated measures. The magnitudes of responses were
not normally distributed, and due to the overdispersion in the data, a Poisson
regression model was not appropriate; hence, using the GEE approach, a neg-
ative binomial model was used to model the rate of change of the responses over
weeks postinfection (13, 36). A P value of 0.05 was considered statistically
significant.
RESULTS
Evolving frequency of HIV-1-specific T-cell recognition and
associations with viral load. We first wished to identify the
evolving frequency of recognition to regions of HIV after acute
infection, using consensus and consensus-like overlapping pep-
tides. Figure 1A shows that Nef, Pol, and Gag were the most
frequently targeted proteins from as early as 3 to 8 weeks
postinfection, rising from more than 50% recognition at 12
weeks to 100% of individuals reactive to one or more of the
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Nef peptide pools at 6 months postinfection. Between 3 to 8
weeks postinfection, when the earliest measurements were
made, the immunodominance of Nef appeared to be estab-
lished, with more than 75% of individuals recognizing the Nef
region, followed by Pol (50%), Gag and Env (47%), Vif (38%),
Vpr (32%), and Rev, Vpu, and Tat (12%). Using a GEE (see
Materials and Methods) to fit the frequency of recognition, we
found that over the first 6 months there was a 23% chance of
an increased response to Nef for every week postinfection (P 
0.0024), followed by a nonsignificant increased response to
both Pol (4.6%) and Gag (3.2%). Responses to Env and the
regulatory proteins remained stable over the first 6 months
postinfection. Collectively, these data show a distinct hierarchy
of the rate of responses during acute infection, with responses
to Nef evolving most rapidly. When using the GEE model to
determine whether a response to a specific region was associ-
ated with increased viral loads, there was a significant (P 
0.0042) odds ratio of 1.86 for responses to Env for every log10
increase in viral load. This translates into an 86% increase in
the chance of having an Env response for every log10 increase
in viral load. Conversely, there was a 35% decreased chance of
having a Gag response for each log10 viral load increase (P 
0.0796) (Fig. 1B). These results mean that although responses
to Env appear to remain stable over the first 6 months of
infection, the recognition of this region relates to a higher rate
of viral load increase, and the recognition of Gag relates to a
lower rate of viral load increase. Of note, responses to Nef and
Pol, the earliest and most immunodominant regions recog-
nized during acute infection, were not associated with any
increased or decreased rates of viral load.
Evolving magnitudes of HIV-1-specific T-cell responses. In
terms of magnitude, the immunodominance of Nef is further
highlighted in Fig. 2A, where a longitudinal analysis shows Nef
to have a significantly higher magnitude of response over time
than any other protein. Responses directed against Nef made
up more than 30% of the total cumulative T-cell response
relative to other proteins and were proportionally higher in
magnitude than those directed against other regions at any
time point analyzed (Fig. 2B). We have previously reported on
specific Nef epitopes recognized at 12 weeks postinfection
(22), and when responses were normalized, taking into account
the amino acid length of the protein for each responder, Nef
was the most immunogenic protein at all time points, corrob-
orating findings of Streeck et al. (48) and Masemola et al. (34).
The highest density of targeted peptides was embedded within
the conserved central region of Nef between amino acids 52 to
171 (22). As the magnitudes of responses to each peptide
region were not normally distributed, a negative binomial
model was used (see Materials and Methods) to model the rate
of change in the magnitude of each response over weeks
postinfection, while also adjusting for repeated measures. Fig-
ure 2C shows that the magnitude of Gag recognition was the
only response which had a significant positive slope (P 
0.0096), where a unit increase in weeks postinfection led to a
log 0.0364 increase in the slope of responses to Gag in the first
6 months postinfection. There was a nonsignificant increase in
the response to Nef (P  0.0943), with a log 0.0218 increase in
the slope of responses to Nef for every week postinfection. The
magnitudes of responses to other regions showed declines or
increased responses over time, but none showed a significant
rate of change over time. Taken together, although Nef re-
sponses were highly immunodominant and increased over 6
months, neither the frequency nor the magnitude had any
impact on the rate of viral load changes. However, the later
emergence of responses to Gag over time, both in frequency
and magnitude, was associated with lower rates of viral load
increases in this cohort. These data provide a unique insight
into the dynamic nature of T-cell responses during acute in-
fection and suggest that neither a static measurement nor the
magnitude of response alone is enough to determine the
course of viremia (22).
Recognition patterns of HIV-1-specific T-cell responses over
time. We investigated a subset of 34 individuals at more inten-
sive time points immediately after infection and identified
three distinct response profiles: (i) lost responses were defined
as a drop of 80% or more in the magnitude of the peak
response over two consecutive time points, (ii) new or emerg-
ing responses were defined as the appearance of detectable
FIG. 1. Frequency of T-cell recognition across the expressed subtype C HIV-1 proteome. (A) Dotted lines represent response frequencies to
Nef, Pol, Gag, Env, Vif, Vpr, Rev, Vpu, and Tat at 6, 12, and 24 weeks postinfection (ranges of weeks postinfection for each time point are
indicated in parentheses). The two horizontal dotted lines represent cutoffs for immunodominant (50%) and subdominant (25%) responses.
(B) Association of viral load with the magnitudes of HIV-1-specific T-cell responses across the entire expressed genome using a generalized
estimating equation model. This model was fitted to the data using a binomial distribution with a logit link, adjusted for repeated measurements
(with an unstructured covariance structure). The horizontal solid line represents an odds ratio of 1.
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IFN- ELISPOT responses to a peptide pool which were not
present at two previous consecutive time points, and (iii) per-
sistent responses were defined as those responses that per-
sisted over time and were characterized by fluctuating recog-
nition profiles. Figure 3A shows each profile, with 36% of
individuals having profile 1 responses, characterized by a rapid
loss of HIV-1-specific IFN- T-cell responses soon after pri-
mary infection; 22% having profile 2 responses, characterized
by responses that were new or emerging over time; and 42%
having profile 3 responses, characterized by responses that
persisted over time. Although the majority of HIV-infected
individuals showed persistent responses, virtually all these re-
sponses showed waxing and waning reactivities over time. To
discount for the possibility of fluctuating responses being due
to assay variability, we determined the coefficient of variation
against CEF peptides in quality control samples to be 24% and
within two standard deviations of the mean IFN- ELISPOT
response (data not shown). The average percentage of fluctu-
ations over time across all persistent responses was well above
the assay coefficient of variation and was 43%. Of note,
oscillations over time in the magnitudes of non-HIV-specific
responses (i.e., CEF, PHA) were also observed for both
HIV-infected and noninfected individuals. Moreover, in
most infected participants, the fluctuation pattern of PHA and
CEF responses mirrored those observed for HIV-specific re-
sponses (data not shown). Taken together, these data show
that variation of HIV-specific responses over time is likely to
be a biological phenomenon and suggest that fluctuations are
a natural physiological phenomenon, reflecting the flexible,
nonstatic nature of T-cell responses that lead to waves of
immunodominance (51).
The fluidity of recognition profiles that constitute an appar-
ent stable response at the overall protein level is shown in Fig.
3B, which illustrates the simultaneous distribution of lost, per-
sistent, and new responses toward Gag, Pol, Env, and Nef.
There were no significant differences between these patterns.
In total, we observed the emergence of 18 new responses with
the concomitant loss of 29 different responses. Although there
were no statistically significant differences between protein re-
gions, there was a trend toward more responses to Nef pep-
tides either persisting or being lost and more new responses to
Pol and Env peptides. These data also underscore that new or
FIG. 2. Magnitude, proportions, and hierarchy of IFN- ELISPOT responses. (A) Cumulative magnitudes of IFN- ELISPOT responses
across the HIV-1 proteome, expressed as spot-forming units (SFU)/106 PBMC, at 5 (range, 3 to 8), 13 (range, 12 to 15), and 22 (range, 20
to 26) weeks postinfection. Each symbol represents a response per participant, and the solid vertical lines represent the upper and lower
ranges, with the median responses as short horizontal bars. (B) Pie charts depicting the relative contributions of Nef, Gag, Pol, Env, and
VVTRV (Vif, Vpr, Tat, Rev, Vpu) to the total magnitude of HIV-1-specific T-cell responses at 5 (range, 3 to 8), 13 (range, 12 to 15), and
22 (range, 20 to 26) weeks postinfection. (C) Rate of change in the magnitudes of HIV-1-specific T-cell responses across the entire expressed
genome over weeks postinfection.
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lost T-cell recognition is not confined to a specific protein
region and that HIV-specific T-cell responses are dynamic and
fluid in nature.
The dynamic nature of T-cell recognition patterns and early
disease progression. We next aimed to identify whether lost,
new, or persistent responses had any impact on early disease
progression in the first 12 months postinfection. Study partic-
ipants were grouped according to defined disease progression
categories (22), and the numbers of lost, new, or persistent
responses were compared between the three groups (Fig. 3C).
Rapid progressors were defined as study participants who had
CD4 counts below 350 cells/ml and viral loads above 100,000
copies/ml on two consecutive measurements between 10 to 15
months postinfection, slow progressors were defined as partic-
ipants having CD4 counts above 350 cells/ml and viral loads
below 2,000 RNA copies/ml on two consecutive measurements
between 10 to 15 months postinfection, and intermediate pro-
gressors were defined as those who fitted neither the rapid nor
the slow category. Individuals with rapid progression (n  9)
possessed significantly fewer (P  0.0037) persistent responses
(profile 3) and a greater number (P  0.06) of new responses
(profile 2) than those with intermediate (or typical) progres-
sion (n  20). The frequencies of lost responses (profile 1)
were equal between the intermediate and rapid progressors.
No loss of IFN- ELISPOT responses was detected for indi-
viduals showing early slow disease progression (n  5), where
these subjects overwhelmingly possessed persistent responses
(89%). These data suggest that persistent responses over time,
recognizing invariant epitopes, may provide advantageous im-
mune responses leading to sustained viral suppression and/or
maintenance of CD4 counts. The loss of response, which was
invariably associated with epitope escape, appeared to provide
no advantage to the host, while new responses which emerged
over time are probably driven by antigen load and therefore
appear deleterious during early HIV infection.
To understand whether a lost response may be due to the
loss of a weak subdominant response, we compared the peak
magnitudes of responses between lost and persistent responses
(Fig. 3D) and found that there was no preferential disappear-
ance of subdominant responses. Furthermore, the magnitudes
FIG. 3. Longitudinal characterization of HIV-1-specific T-cell responses over the first year of infection. (A) Tracking of HIV-1 specific T-cell
responses over time showing three distinct profiles of T-cell recognition; (B) proportion of IFN- ELISPOT responses that are lost, persistent, or
new to Nef, Gag, Pol, and Env when followed longitudinally over 1 year; (C) proportion of lost, persistent, and new IFN- ELISPOT responses
in rapid progressors (n  10), intermediate progressors (n  33), and slow progressors (n  8); (D) peak magnitudes of lost or persistent IFN-
ELISPOT responses.
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of peak responses for each recognition profile were unrelated
to disease categories of rapid, intermediate, and slow (Fig. 3D).
Collectively, these data suggest that single-peptide responses that
are lost, emerge as new responses, or persist during the first year
of infection are not associated with high or low initial peak mag-
nitudes of responses during acute infection.
Recognition patterns associated with autologous viral es-
cape. Our approach to identify lost, persistent, or new IFN-
responses was made using peptide pools. After deconvoluting
the peptide-matrix pools in the ELISPOT assay (34) and con-
firming single-peptide responses in follow-up assays, we were
able to verify that many of the pool responses were derived
from the recognition of one immunodominant peptide re-
sponse. Figure 4 shows the correlation between the peptide
pool responses initially identified and the single peptides used
to confirm the responses. For Gag and Nef, there were highly
significant correlations between peptide pool responses and
confirmed single peptides, where the peptide confirmations
falling into profile 1 showed r values of 0.869 (P  0.0004) and
0.8154 (P  0.0001) for Gag and Nef, respectively, and profile
2 showed an r value of 0.854 (P  0.0001) for Nef. The corre-
lation of overall peptide pool responses with single peptides
(regardless of the profile of response) showed significant
correlations for Gag (r  0.756; P  0.0001), Nef (r 
0.8007; P  0.0001), Pol (r  0.7613; P  0.0001), and Env
(r  0.5914; P  0.0002) (Fig. 4). Tables 1 and 2 show the
confirmed peptides that constitute the responses identified in
the peptide pool responses for Gag and Nef, identifying the
likely epitopes within the peptide being targeted and those
which are associated with lost, new, or persistent responses.
When we overlaid the recognition profile with autologous
viral sequence changes, it was evident that profile 1 (lost re-
sponses) were mostly observed concurrently with fixed viral
escape over time (87.5% [14 of 16]) (Fig. 5A), where escape
occurred either in the putative epitope (E) or in the flanking
region (F). Table 1 shows the peak T-cell response in 14 of the
T-cell responses with profile 1 at the single-peptide level and
the timing of viral epitope escape. Fifty percent of profile 2
responses (new/emerging responses) were associated with au-
tologous sequence variation; however, the low number of in-
dividuals (n  4) presenting with new responses to Gag or Nef
did not allow us to draw defined conclusions (Fig. 5B). Profile
3 responses (persistent responses) were least associated with
autologous viral escape, with 37% (7 of 19) showing epitope
variation, or almost two-thirds of participants with invariant
sequences. In the representative example shown in Fig. 5A,
study participant CAP217 possessed a peak IFN- ELISPOT
response of 2,190 spot-forming units (SFU)/106 PBMC at 12
weeks postinfection, recognizing the HLA-B*5801-restricted
TW10 (TSTLQEQIAW) epitope in p24 Gag (Table 1). By 17
weeks postinfection, a fixed T3N mutation occurred at posi-
tion 3, and by 19 weeks postinfection, the response fell below
80% of the peak response (Table 1). For CAP88, there was a
relatively weaker peak IFN- ELISPOT response of 465 SFU/
106 PBMC at 7 weeks postinfection, recognizing a probable
HLA-B*4501-restricted AS9 (AEAMSQANS) epitope in p15
Gag. There was a subsequent transient escape in the flanking
region detected by 13 weeks postinfection that was associated
with reduction in responses to 138 SFU/106 PBMC. It was
interesting to note that although there was a reversion back
FIG. 4. Correlations between peptide pool responses and confirmed single peptides. Spearman correlations between IFN- ELISPOT re-
sponses derived from the peptide pool versus single confirmed peptides within the pool for Gag, Nef, Pol, and Env. The black circles represent
peptide pools versus single peptides for all responses, open circles represent peptide pools versus single peptides for peptides that showed evidence
for autologous viral sequence change, and crosses represent peptide pools versus single peptides for peptides that showed persistent IFN-
ELISPOT responses.
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from valine to alanine at amino acid position 374 at some point
between 26 and 54 weeks postinfection, there was no detect-
able IFN- ELISPOT response during this time (Fig. 5A).
CAP256, showing a profile 2 pattern, possessed a late peak
IFN- ELISPOT response (2,935 SFU/106 PBMC) at 34 weeks
postinfection. It was evident from the autologous sequence
change within the recognized epitopic region (probable HLA-
Cw*0602-restricted AL9 [AAFDLSFFL] [Table 1]) that the
initial nonrecognition of the peptide used in the assay was due
to sequence variation in the flanking region and within the
epitope (Fig. 5B). By 30 weeks postinfection, the infecting
virus sequence (measured at 6 weeks postinfection) changed to
match the peptide sequence. Of note in this individual, more
than 80% of the peak IFN- ELISPOT response was lost,
regained, and then lost despite there being no further varia-
tions in the autologous sequence (Fig. 5B). CAP210 showed a
profile very similar to that of CAP256, where there were two
putative epitopes being recognized: HLA-B*1510-restricted
YVDRFFKTL and HLA Cw*0304-restricted RAEQATQD in
p15 Gag (Table 2). However, in contrast to CAP256, CAP210
showed no detectable autologous sequence variation despite
showing a peak IFN- ELISPOT response of 2,068 SFU/106
PBMC (Table 2) at 30 weeks postinfection (Fig. 5B). Both
CAP225 and CAP257 represented individuals with a profile 3
pattern, showing persistent IFN- ELISPOT responses in
the absence of autologous sequence variation, despite high-
TABLE 1. Confirmed variant peptide responses in 17 study participants in Gag and Nef, showing the profile of response over time, disease
category, region of viral variation within the putative epitope, peak IFN- ELISPOT response, time to autologous viral
epitope escape, and subsequent time to loss of peptide-specific responses
Participant
identifier Protein Confirmed peptide response




















CAP8 p17 9GKKHYMLKHLVWASREL26 A*2301/-, B*0801/15:10,
C*0701/1601
1 R E 2,695 11.5 30
CAP37 Nef 6SKSSIVGWPAVRERIRRTE24 A*2301/2402, B*0702/
5301, C*1701/-
1 R F 2,243 13
CAP37 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*2301/2402, B*0702/
5301, C*1701/-
1 R FE 5,653 9.5 15
CAP85 Nef 113WVYHTQGYFPDWQNYTPGP131 A*3002/-, B*0801/4501,
C*0701/1601
1 I F 1,638 18.5 16
CAP88a p15 357SHKARVLAEAMSQANSA374 A*2902/6601, B*4501/
5802, C*0602/-
1 I F 465 10 26
CAP129 Nef 65EVGFPVRPQVPLRPMTYKA93 A*2601/8001, B*1801/
8101, C*0202/0401
1 I E 155 2 13
CAP129 Nef 101IHSKRRQDILDLWVYYHTQG119 A*2601/8001, B*1801/
8101 C*0202/0401
1 I FE 1,775 2 13
CAP217 p24 234SDIAGTTSTLQEQIAWMTSNPPVPV2 A*0202/2901, B*1503/
5801, C*0210/0602
1 I E 2,190 14.5 19
CAP217 Nef 77RPMTYKAAFDLSFFLKEKG95 A*0202/2901, B*1503/
5801, C*0210/0602
1 I E 3,528 17.5 19
CAP225a Nef 125QNYTPGPGVRYPLTF139 A*0101/3001, B*4202/
8101, C*1701/1801
1 I E 2,468 1.5 29
CAP225a Nef 161NNCLLHPMSQHGMEDADRE179 A*0101/3001, B*4202/
8101, C*1701/1801
1 I E 1,248 28.5 33
CAP229a p24 234SDIAGTTSTLQEQIAWMTSNPPVPV2 A*0123/-, B*5801/-,
C*0602/-
1 I F 1,188 18.5 34
CAP255 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*0301/8001, B*0801/
1801, C*0202/0702
1 I E 2,688 24.5 51
CAP264 Nef 77RPMTYKAAFDLSFFLKEKG95 A*3601/6802, B*1510/
5301, C*0401/0804
1 I E 2,725 17.5 20
CAP8 Nef 101IHSKRRQDILDLWVYYHTQG119 A*2301/-; B*0801/1510;
Cw*0701/1601
2 R FE 2,495 11.5
CAP256 Nef 77RPMTYKAAFDLSFFLKEKG95 A*2901/6601; B*1503/
5802; Cw*0401/0602
2 R E 2,935 21
CAP30 Nef 77RPMTYKAAFDLSFFLKEKG95 A*0201/3402; B*4403/
4501; Cw*0401/1601
3 I E 313 8
CAP244 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*2301/3004; B*4403/
5802; Cw*0401/0602
3 I F 5,735 52
CAP255 Nef 101IHSKRRQDILDLWVYYHTQG119 A*0301/8001; B*0801/
1801; Cw*0202/0702
3 I FE 4,045
CAP258 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*2301/2902; B*4101/
4201; Cw*1701/-
3 R E 4,245 19.5
CAP261 Nef 101IHSKRRQDILDLWVYYHTQG119 A*2911/4301; B*1302/
1503; Cw*0602/-
3 I FE 300 5
CAP262a Nef 65EVGFPVRPQVPLRPMTYKA93 A*0101/6602; B*4201/
8101; Cw*06/1701
3 S E 935 14
CAP268a Nef 101IHSKRRQDILDLWVYYHTQG119 A*0205/2601; B*0705/
5801; Cw*0701/0702
3 I FE 1,543 4
Mean  SD 2,313  1,563 14  11 24  11
a This study participant showed a simultaneous profile of lost and persistent peptide-specific responses.
b Bold and underlining represent the putative optimal epitope.
c Bold and underlining represent the putative restricting HLA. Hyphens refer to the same HLA allele and depict a homozygous locus.
d R, rapid progressor; I, intermediate progressor; S, slow progressor.
e E, mutation occurs within the targeted epitope; F, mutation occurs within the flanking region of the targeted epitope.
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magnitude peak responses of several thousand SFU/106
PBMC (Table 2 and Fig. 5C). Collectively, when we assessed
the Shannon entropy scores for the peptides falling into either
profile 1 or profile 3, we found there to be no significant
difference.
Decay of IFN- ELISPOT responses after epitope escape.
Assessing the tempo of lost IFN- ELISPOT responses in
relation to autologous viral escape, we were able to show a
strong association between the estimated time of viral escape
and the time to disappearance of the IFN- ELISPOT re-
sponse (P  0.019; r  0.61). For the 10 individuals and 14
epitopes showing escape (Table 1), we estimated the time
taken for the IFN- ELISPOT response to decay after the
target epitope varied (Fig. 6) to be a mean 14 weeks (range, 4.4
to 24 weeks, 95% confidence interval). These data indicate that
once the presenting epitope was removed, there was likely no
requirement for the continued survival of IFN--producing
effector T cells, which dissipated between 1 and 6 months after
epitope escape.
DISCUSSION
In a cohort of 53 subjects infected with subtype C HIV-1, we
recently reported that the breadth and magnitude of HIV-1-
specific IFN- ELISPOT T-cell responses at 3 months postin-
fection were unrelated to the viral set point at 12 months
postinfection and that there was a dominant, narrow, and fo-
cused recognition of Nef at 3 months postinfection (22). In the
current paper, we investigated the dynamics and kinetics of
IFN- ELISPOT T-cell responses over time in this cohort. We
found a strong and diverse pattern of T-cell recognition across
the entire HIV-1 proteome, with immunodominant responses
emerging as early as 3 weeks postinfection. Consistent with
previously reported immunodominance patterns of T-cell rec-
ognition, Nef, Pol, and Gag were the most frequently recog-
nized regions during the first 6 months of infection (22, 31, 34,
48), with a distinct hierarchy of evolving responses. In this
cohort, Nef responses were the most rapid to emerge over
time, being dominant at all time points analyzed, in agreement
with other publications (31, 34, 35, 48). However, despite the
vigorous targeting of Nef, we found no association between
anti-Nef-specific T-cell responses and viral load. This contrasts
with studies that have demonstrated a direct correlation be-
tween Nef-specific T-cell responses and high viremia in early
and chronic HIV-1 infection (25, 34, 55). However, our anal-
ysis takes into account the temporal patterns of response, mak-
ing this analysis unique from previous studies. Of note, of the
responses to increase over time, anti-Gag-specific T cells
emerged the slowest.
In agreement with previous findings (15, 25, 34, 48, 55), the
frequencies of Gag- and Env-specific T-cell responses were
TABLE 2. Confirmed invariant peptide responses in 13 study participants in Gag and Nef, showing the profile of
response over time, disease category, and peak IFN- ELISPOT responses
Participant
identifier Protein Confirmed peptide response













CAP174 Nef 73QVPLRPMTYKAAFDL87 A*0301/7401; B*4901/5802;
Cw*0602/0701
1 R 923 11
CAP229a Nef 77RPMTYKAAFDLSFFLKEKG95 A*0123/-; B*5801/-;
Cw*0602/-
1 I 1,808 15
CAP210 p15 290KEPFRDYVDRFFKTLRAEQATQD321 A*6802/-; B*1510/-;
Cw*0304/-
2 R 2,068
CAP228 p24 163AFSPEVIPMFTALSEGA179 A*2301/2638; B*4403/5101;
Cw*0303/0701
2 S 320
CAP45 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*2301/2902; B*1510/4501;
Cw*0602/1601
3 S 2,178
CAP88a Nef 113WVYHTQGYFPDWQNYTPGP131 A*2902/6601; B*4501/5802;
Cw*0602/-
3 I 2,677
CAP206 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*0301/3201; B*0702/4403;
Cw*0210/0702
3 R 243
CAP222 Nef 65EVGFPVRPQVPLRPMTYKA93 A*3001/3303; B*5301/8101;
Cw*0401/-
3 S 2,838
CAP222 p24 178GATPQDLNTMLNTVGGH194 A*3001/3303; B*5301/8101;
Cw*0401/-
3 S 1,568
CAP225a p24 178GATPQDLNTMLNTVGGH194 A*0101/3001; B*4202/8101;
Cw*1701/1801
3 I 3,327
CAP228 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*2301/2638; B*4403/5101;
Cw*0303/0701
3 S 2,915
CAP257 p17 9GKKHYMLKHLVWASREL26 A*2301/2902; B*4202/4403;
Cw*1701/-
3 I 775
CAP257 Nef 129PGPGVRYPLTFGWCFFKLVP147 A*2301/2902; B*4202/4403;
Cw*1701/-
3 I 4,928
CAP262a p24 178GATPQDLNTMLNTVGGH194 A*0101/6602; B*4201/8101;
Cw*06/1701
3 S 1,335
CAP268a p24 235DIAGTTSTLQEQIAWMTSNPPVPV258 A*0205/2601; B*0705/5801;
Cw*0701/0702
3 I 2,325
Mean  SD 2,015  1,245
a This study participant showed a simultaneous profile of lost and persistent peptide-specific responses.
b Bold and underlining represent the putative optimal epitope.
c Bold and underlining represent the putative restricting HLA. Hyphens refer to the same HLA allele and depict a homozygous locus.
d R, rapid progressor; I, intermediate progressor; S, slow progressor.
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found to be associated with lower and higher viremia, respec-
tively, supporting the hypothesis that the ability to target Gag
in vivo contributes to viral control. Further support for the
importance of Gag is when mutations in key epitopes result in
a fitness cost to the virus. For example, in this cohort, we have
previously found that lower viremia was noted for HIV-
infected individuals after viral transmission with viruses con-
taining B*57/58 escape mutations to HLA-B*57/B58-nega-
tive recipients, suggesting that mutations in the ISW9/TW10
Gag epitopes are associated with a transmitted viral fitness
cost (10, 11).
One of the major factors limiting the effectiveness of virus-
specific CTL is the ability of HIV-1 to evade CTL responses
through sequence variation or viral escape (1, 19). Longitudi-
nal studies of CTL escape suggest that CTL responses repre-
sent a major driving force of HIV, SIV, and hepatitis C virus
evolution, with more than 50% of sequence variation across
the genome attributed to CTL-mediated pressure in SIV and
FIG. 5. Profiles of T-cell recognition in relation to autologous sequence variations in Gag and Nef. Representative examples of the three T-cell
recognition profiles in relation to autologous sequence variation, shown as the magnitudes of IFN- ELISPOT responses over weeks postinfection.
Each example is a representative individual within the cohort, showing the high-resolution HLA background for A, B, and C alleles. The sequences
of the autologous virus at different weeks postinfection are shown underneath each graph. The gray shaded areas indicate the putative targeted
epitope. The boxes with dashed borders on the graphs show the windows of time in which autologous viral escape occurred. “E” corresponds to
a mutation within the target epitope, and “F” corresponds to a mutation in the flanking region of the targeted epitope.
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HIV (1, 28, 40). In this paper, we show that the magnitude of
HIV-specific T-cell responses fluctuates widely over the first
year of infection, highlighting the rapidity of T-cell evolution
and the often unpredictable nature of T-cell recognition
patterns. Three distinct profiles of T-cell recognition were
identified, characterized by either lost, new, or persistent
responses, and there was a tendency of lost and persistent
responses to be clustered in Nef and emerging new responses
to be clustered in Pol and Env. Almost 90% of lost T-cell
recognition (profile 1) was coincidental with autologous se-
quence variation in either the putative or the flanking region of
epitopes and was consistent with CTL immune pressure. In
support of this, CTL-driven immune escape has been demon-
strated in the acute phase of SIV and HIV infection, suggesting
a rapid selection or evasion of virus-specific CTL responses
during the first few weeks of infection (1, 5, 8, 17, 30). Using
single-genome amplification (SGA), IFN- ELISPOT assay,
and algorithms to identified sites of positive selection across
the HIV genome, Goonetilleke et al. (17) identified the first
T-cell responses to the transmitted/founder virus and showed
that these T-cell responses rapidly select escape mutations
concurrent with a decrease in viral load in acute HIV-1 infec-
tion. These data provide insight into the contribution of CTL
in the resolution of acute-phase viremia. There is also strong
inferential evidence supporting HLA class 1-driven viral evo-
lution across the HIV-1 genome in both subtype B and C HIV
infection (4, 9, 14, 23, 44, 50, 53), where a high density of
HLA-associated mutation sites can be found in Nef relative to
Pol, Gag, and other regulatory proteins, suggesting that CTL
recognition exerts differential selection pressures in selected
regions (9, 44, 53). This also may explain the high proportion
of lost responses in Nef relative to Gag, Pol, and Env that we
observed. Toggling selection sites, defined as a model of pos-
itive selection associated with immune escape and reversion,
have also been observed for Nef, consistent with the high
density of HLA-associated polymorphisms (12), supporting the
evidence of CTL-driven immune selective pressure in shaping
HIV diversity. It is noteworthy, however, that the use of con-
sensus and consensus-like peptides in our study might under-
estimate or limit the potential to detect HIV-1-specific CTL
responses, especially to those highly variable regions of the
HIV-1 genome. Ideally, the use of autologous sequence-based
peptide sets may have improved our detection of T-cell re-
sponses in more variable regions of HIV-1 proteins than pre-
viously reported (2) and would have provided a more compre-
hensive profile of the evolution of T-cell responses from acute
to chronic HIV infection. It is probable that the use of autol-
ogous peptides based on the transmitted infecting virus would
avoid the potential underestimation of epitope escape.
Similar to Turnbull et al. (51), we found a relatively low
proportion of autologous sequence variation within epitopic
regions being targeted by persisting HIV-specific T cells in this
study, suggesting that the fluctuations we observed for many of
the persisting responses were due to mechanisms other than
viral escape. Several mechanisms have been postulated for the
temporal fluctuation of CTL responses, including (i) fluctua-
tions in antigen load, (ii) divergence of the CD8 T-cell re-
ceptor (TCR) repertoire, and (iii) T-cell exhaustion (16, 38,
51). Other studies have reported perturbations of the T-cell
receptor repertoire during primary HIV infection and hypoth-
esized that this may be influenced by the clonal expansion and
exhaustion of virus-specific CTL clones during the initial burst
of viremia during acute infection (18, 41, 46). It has also been
hypothesized that persistence of some epitopes are due to
insufficient antiviral pressure from the corresponding CTL re-
sponses (26). In addition, conserved epitopes have been shown
to elicit subdominant CTL responses throughout HIV-1 infec-
tion (32). However, in our study, there were no differences
between subdominant or dominant T-cell responses in persis-
tent or lost epitopes, which appeared to have no bearing on
disease progression in our study. These data are in agreement
with the findings of Lui et al. (33), who found no differences in
the peak magnitudes of CTL responses between evolving and
persistent epitopes. Based on the fact that persistent T-cell
responses tended to target peptides preferentially with low
variability, we could hypothesize that persistent immune re-
sponses are directed against highly conserved epitopes (those
with low entropy) and that the three different profiles of re-
sponses are a likely result of the structurally constrained nature
of the epitopes targeted. However, no differences were ob-
served in the average entropy scores of peptides within the
differing profiles, making it difficult to associate the likelihood
of epitope change with the profile of the T-cell response. Our
data also suggest that the temporal nature of T-cell fluctua-
tions means that a static measurement in time is not a predict-
able or reliable marker of recognition and may have little
meaning for disease progression. The significance and nov-
elty of these results lie at several levels: (i) T-cell epitope
recognition is not a static event and there are temporal
patterns of IFN--based responses, (ii) persistent T-cell re-
sponses to invariant epitopes are enriched in individuals
with slowly progressing viremia, and (iii) it takes an average
of 14 weeks for IFN--based T-cell responses to dissipate
once the target epitope has escaped. Collectively, the
broader interpretation of our data is that continual invariant
viral epitope presentation is required for persistent T-cell
immunity, which in turn appears necessary for the control of
early disease progression.
FIG. 6. Relationship between the time of loss of IFN- responses
and the median time of viral escape or autologous sequence variation.
Linear regression showing a linear correlation between the estimated
median time of autologous epitope escape and the time of IFN-
ELISPOT response loss. The dashed lines indicate the 95% confidence
intervals (c.i.) above and below the mean regression line. The esti-
mated time of escape was calculated as the median time between the
last time point measured where the autologous sequence was wild type
and the first time point where the variant sequence was detected.
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